ANI Pharmaceuticals, Inc. Forecast, price target & analysts
ANI Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
ANI Pharmaceuticals, Inc. Classifications & Recommendation
ANI Pharmaceuticals, Inc. Price Target
| Target Price | $106.08 |
| Price | $72.18 |
| Potential |
46.97%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target ANI Pharmaceuticals, Inc. 2027 .
The average ANI Pharmaceuticals, Inc. target price is $106.08.
This is
46.97%
register free of charge
$127.05
76.02%
register free of charge
$90.90
25.94%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend ANI Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ANI Pharmaceuticals, Inc. stock has an average upside potential 2027 of
46.97%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 883.37 | 1,124.00 |
| 43.78% | 27.24% | |
| EBITDA Margin | 23.29% | 26.40% |
| 72.48% | 13.34% | |
| Net Margin | 7.95% | 19.36% |
| 342.37% | 143.55% |
10 Analysts have issued a sales forecast ANI Pharmaceuticals, Inc. 2026 . The average ANI Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an ANI Pharmaceuticals, Inc. EBITDA forecast 2026. The average ANI Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 ANI Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average ANI Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 3.32 | 9.47 |
| 419.23% | 185.24% | |
| P/E | 7.62 | |
| EV/Sales | 1.68 |
10 Analysts have issued a ANI Pharmaceuticals, Inc. forecast for earnings per share. The average ANI Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
ANI Pharmaceuticals, Inc....
Current ANI Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jul 17 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jul 10 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jan 16 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Dec 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jul 17 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jul 10 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jan 16 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Dec 09 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
